🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Health Concern

The sexually transmitted infection are on the rise around the world, with figures suggesting over 82 million new cases each year. Particularly high rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Public health authorities are deeply concerned about the surge in drug-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in concurrent days. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization marks a huge turning point in the treatment of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Research Study Results and Global Access

According to findings published in a major medical journal, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which involves an injection and a pill. The trial included nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in many regions with limited resources.

Medical professionals directly involved have voiced positive views. Having a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is deemed essential to alleviate the strain of the disease for patients and to halt the transmission of untreatable gonorrhoea globally.